123I-ALTROPANE® Reference Image Acquisition in Subjects With Diagnostically Uncertain Tremor

Exclusion Criteria

• •1. Any clinically significant acute or unstable physical or psychological illness based on medical history or physical examination at Visit 1, as determined by the Principal Investigator;
• •2. Any unexpected clinically significant abnormal laboratory or ECG results obtained at Visit 1 and as determined by the Principal Investigator;
• •3. Any history of drug, narcotic, or alcohol abuse within 2 years prior to the date of informed consent, as defined by the Diagnostic and Statistical Manual of the American Psychiatric Association, 4th Edition (DSM-IVR {American Psychiatric Association, 1994 #2});
• •4. Positive urine drug screen at Visit 1;
• •5. Participation in an investigational drug or device clinical trial within 30 days prior to the date of informed consent;
• •6. Previous participation in any 123I-ALTROPANE® trial;
• •7. Any exposure to radiopharmaceuticals within 30 days prior to the date of informed consent;
• •8. Positive (+) pregnancy test at Visit 1 and/or Visit 2;
• •9. Breast-feeding;
• •10. Inability to lie supine for 1 hour;
• •11. Any significant active thyroid disease;
• •12. Known sensitivity or allergy to Iodine or Iodine containing products;
• •13. A history of repeated head injury or sustained severe head injury in year prior to onset of tremor;
• •14. A definitive diagnosis of encephalitis;
• •15. Any uncontrolled hypertension or diabetes;
• •16. Any history of cerebrovascular disease;
• •17. Previous evaluation by a Movement Disorder Specialist (MDS);
• •18. Treatment within the previous six (6) months prior to informed consent with bupropion, metoclopramide, cinnarizine, flunarizine, methylphenidate, reserpine, modafinil, alpha methyldopa, amphetamine, or any anti-psychotic medication;
• •19. Any treatment with anti-Parkinson's drugs or anti-tremor medications within three (3) months prior to the date of the subject signing the informed consent;
• •20. Any new prescription or change in dose of medications for chronic conditions within four (4) weeks of Visit 2.